Bristol-Myers Squibb Q1 Earnings Beat Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Source: seekingalpha
- Strong Financial Performance: Bristol-Myers Squibb reported $11.5 billion in revenue for Q1 2026, reflecting a ~3% year-over-year growth that exceeded market expectations by $580 million, demonstrating the company's financial resilience amid challenges.
- Growth Portfolio Outperformance: The growth portfolio contributed $6.2 billion in revenue with ~12% year-over-year growth, driven by cancer therapy Opdivo and rheumatoid arthritis drug Orencia generating $2.1 billion and $818 million, respectively, indicating strong market acceptance of new product lines.
- Legacy Product Decline: Despite the strong performance of the growth portfolio, the legacy product line contracted ~6% year-over-year, generating $5.3 billion, highlighting the impact of generics on other products and the need for a faster transition to maintain competitive positioning.
- Reaffirmed Full-Year Outlook: The company reaffirmed its full-year revenue guidance of $46.0 billion to $47.5 billion and adjusted EPS of $6.05 to $6.35, aligning with market consensus, reflecting management's confidence in future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to rise
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 55.390
Low
37.00
Averages
55.86
High
68.00
Current: 55.390
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strategic Comparison of Johnson & Johnson and Bristol Myers Squibb
- Financial Performance Comparison: Bristol Myers Squibb reported approximately $48.2 billion in revenue for FY 2025 with a net income of $7.1 billion, reflecting a net margin of 14.6%, indicating a recovery despite a slight revenue decline; in contrast, Johnson & Johnson achieved $94.2 billion in revenue with nearly $26.8 billion in net income and a robust net margin of 28.5%, showcasing strong profitability and growth potential.
- Debt and Liquidity Analysis: Bristol Myers Squibb has a debt-to-equity ratio of 2.6x and a current ratio of 1.3, indicating high financial leverage but good short-term solvency; in comparison, Johnson & Johnson's debt-to-equity ratio stands at 0.6x with a current ratio of 1.0, reflecting a more conservative financial position and stronger short-term debt coverage.
- Market Risk Assessment: Bristol Myers Squibb faces significant pressure from the Inflation Reduction Act, which could impact pricing power on key drugs, alongside risks from losing market exclusivity on critical products; meanwhile, Johnson & Johnson is managing substantial legal risks, particularly from long-standing litigation over talc-based products, and is also affected by government price negotiations.
- Valuation Comparison: Bristol Myers Squibb trades at a forward P/E of 8.8x and a P/S ratio of 2.4x, indicating a significant discount compared to Johnson & Johnson, which has a forward P/E of 20.8x and a P/S ratio of 6.2x, reflecting higher market expectations for its future growth and stronger investor confidence.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS
- Drug Development Progress: Quantum BioPharma is advancing Lucid-MS, a novel drug candidate targeting multiple sclerosis by directly protecting the myelin sheath, with plans to enter phase 2 clinical trials that could transform current treatment paradigms.
- Significant Market Demand: The global market for MS therapeutics is projected to reach $27.4 billion in 2024 and grow to $38.62 billion by 2030, highlighting the urgent need for effective treatments, with Quantum BioPharma's innovative drug poised to address this gap.
- Successful Clinical Trials: The phase 1 clinical trial for Lucid-MS has been successfully completed, demonstrating a favorable safety profile and good tolerability, laying the groundwork for subsequent patient trials that could offer unprecedented potential for restoring lost functions.
- Collaborative Research Prospects: Quantum BioPharma is collaborating with Massachusetts General Hospital to utilize advanced imaging techniques to assess Lucid-MS's effectiveness, which could provide direct evidence of the drug's clinical impact and further accelerate its path to market.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS into Phase 2 Trials
- Drug Development Progress: Quantum BioPharma's Lucid-MS is advancing into Phase 2 clinical trials, aiming to directly target the myelin sheath in multiple sclerosis (MS) patients, potentially filling a significant gap in current treatments and improving patient quality of life.
- Significant Market Potential: The global market for MS therapeutics was valued at approximately $27.4 billion in 2024 and is projected to reach $38.62 billion by 2030, highlighting the urgent need for effective therapies, with Quantum BioPharma's innovative drug poised to capture a substantial share.
- Successful Clinical Trials: Lucid-MS demonstrated a favorable safety and tolerability profile in Phase 1 trials, successfully completing dosing among healthy volunteers, laying the groundwork for subsequent patient trials, and offering new hope for MS patients if results are positive.
- Strong Scientific Team: Quantum BioPharma boasts a top-tier scientific team, including experts with extensive experience in medicinal chemistry and neurology, ensuring a rigorous development process for Lucid-MS, which aims to be the first treatment to directly protect the myelin sheath.
See More
Calidi Biotherapeutics Appoints New Independent Director
- New Board Member: Calidi Biotherapeutics announced the appointment of Corsee Sanders as an independent director effective June 17, 2026, leveraging her 23 years of leadership experience at Genentech/Roche to provide strategic guidance.
- Extensive Industry Background: Sanders previously served as Executive Vice President of Development Operations at Juno and acted as a strategic advisor to the Chief Medical Officer post-Celgene acquisition, highlighting her deep expertise in the biopharmaceutical sector.
- Current Board Positions: Currently, Sanders holds board positions at Legend Biotech, Ultragenyx Pharmaceutical, and AltruBio, further enhancing her influence within the biotechnology industry.
- Stock Price Fluctuation: Calidi's stock has traded between $0.12 and $19.20 over the past year, closing at $0.1560, indicating a cautious market sentiment regarding the company's future prospects.
See More
Analysis of FDL's 52-Week High and Low Points
- Price Fluctuation Analysis: FDL's 52-week low is $41.515 and high is $51.46, with the latest trade at $49.41, indicating price volatility within this range that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding helps identify those experiencing notable inflows (new units created) or outflows (old units destroyed), allowing assessment of their impact on underlying assets.
See More
Bristol Myers Squibb Faces Patent Cliff Challenges
- Patent Cliff Risk: Bristol Myers Squibb's two drugs, Eliquis and Opdivo, generated $24.4 billion in sales in 2022, accounting for about half of total revenue; however, both will lose market exclusivity in 2028, potentially leading to a significant sales decline and pressure on future growth.
- Pipeline Investment: The company has 50 compounds in development and aims to launch 10 new medicines by 2029, with Cobenfy already approved for schizophrenia; if it secures approval for Alzheimer's-related psychosis, it could greatly enhance commercial potential, but uncertainty remains as crucial phase 3 trial results are due later this year.
- Stable Dividend Yield: Bristol Myers Squibb offers a dividend yield of 4.6%, with payouts currently only 40% of projected 2026 earnings, meaning even if sales of Eliquis and Opdivo plummet, the company can still afford its dividends, providing investors with a solid margin of safety.
- Attractive Valuation: The stock trades at a low P/E ratio of 8.5, significantly below the industry average of 25, indicating the market's low growth expectations; however, if the company achieves moderate growth during the patent cliff, combined with a high dividend yield, investors could still see substantial returns.
See More
Strategic Comparison of Johnson & Johnson and Bristol Myers Squibb
- Financial Performance Comparison: Bristol Myers Squibb reported approximately $48.2 billion in revenue for FY 2025 with a net income of $7.1 billion, reflecting a net margin of 14.6%, indicating a recovery despite a slight revenue decline; in contrast, Johnson & Johnson achieved $94.2 billion in revenue with nearly $26.8 billion in net income and a robust net margin of 28.5%, showcasing strong profitability and growth potential.
- Debt and Liquidity Analysis: Bristol Myers Squibb has a debt-to-equity ratio of 2.6x and a current ratio of 1.3, indicating high financial leverage but good short-term solvency; in comparison, Johnson & Johnson's debt-to-equity ratio stands at 0.6x with a current ratio of 1.0, reflecting a more conservative financial position and stronger short-term debt coverage.
- Market Risk Assessment: Bristol Myers Squibb faces significant pressure from the Inflation Reduction Act, which could impact pricing power on key drugs, alongside risks from losing market exclusivity on critical products; meanwhile, Johnson & Johnson is managing substantial legal risks, particularly from long-standing litigation over talc-based products, and is also affected by government price negotiations.
- Valuation Comparison: Bristol Myers Squibb trades at a forward P/E of 8.8x and a P/S ratio of 2.4x, indicating a significant discount compared to Johnson & Johnson, which has a forward P/E of 20.8x and a P/S ratio of 6.2x, reflecting higher market expectations for its future growth and stronger investor confidence.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS
- Drug Development Progress: Quantum BioPharma is advancing Lucid-MS, a novel drug candidate targeting multiple sclerosis by directly protecting the myelin sheath, with plans to enter phase 2 clinical trials that could transform current treatment paradigms.
- Significant Market Demand: The global market for MS therapeutics is projected to reach $27.4 billion in 2024 and grow to $38.62 billion by 2030, highlighting the urgent need for effective treatments, with Quantum BioPharma's innovative drug poised to address this gap.
- Successful Clinical Trials: The phase 1 clinical trial for Lucid-MS has been successfully completed, demonstrating a favorable safety profile and good tolerability, laying the groundwork for subsequent patient trials that could offer unprecedented potential for restoring lost functions.
- Collaborative Research Prospects: Quantum BioPharma is collaborating with Massachusetts General Hospital to utilize advanced imaging techniques to assess Lucid-MS's effectiveness, which could provide direct evidence of the drug's clinical impact and further accelerate its path to market.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS into Phase 2 Trials
- Drug Development Progress: Quantum BioPharma's Lucid-MS is advancing into Phase 2 clinical trials, aiming to directly target the myelin sheath in multiple sclerosis (MS) patients, potentially filling a significant gap in current treatments and improving patient quality of life.
- Significant Market Potential: The global market for MS therapeutics was valued at approximately $27.4 billion in 2024 and is projected to reach $38.62 billion by 2030, highlighting the urgent need for effective therapies, with Quantum BioPharma's innovative drug poised to capture a substantial share.
- Successful Clinical Trials: Lucid-MS demonstrated a favorable safety and tolerability profile in Phase 1 trials, successfully completing dosing among healthy volunteers, laying the groundwork for subsequent patient trials, and offering new hope for MS patients if results are positive.
- Strong Scientific Team: Quantum BioPharma boasts a top-tier scientific team, including experts with extensive experience in medicinal chemistry and neurology, ensuring a rigorous development process for Lucid-MS, which aims to be the first treatment to directly protect the myelin sheath.
See More
Calidi Biotherapeutics Appoints New Independent Director
- New Board Member: Calidi Biotherapeutics announced the appointment of Corsee Sanders as an independent director effective June 17, 2026, leveraging her 23 years of leadership experience at Genentech/Roche to provide strategic guidance.
- Extensive Industry Background: Sanders previously served as Executive Vice President of Development Operations at Juno and acted as a strategic advisor to the Chief Medical Officer post-Celgene acquisition, highlighting her deep expertise in the biopharmaceutical sector.
- Current Board Positions: Currently, Sanders holds board positions at Legend Biotech, Ultragenyx Pharmaceutical, and AltruBio, further enhancing her influence within the biotechnology industry.
- Stock Price Fluctuation: Calidi's stock has traded between $0.12 and $19.20 over the past year, closing at $0.1560, indicating a cautious market sentiment regarding the company's future prospects.
See More
Analysis of FDL's 52-Week High and Low Points
- Price Fluctuation Analysis: FDL's 52-week low is $41.515 and high is $51.46, with the latest trade at $49.41, indicating price volatility within this range that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding helps identify those experiencing notable inflows (new units created) or outflows (old units destroyed), allowing assessment of their impact on underlying assets.
See More
Bristol Myers Squibb Faces Patent Cliff Challenges
- Patent Cliff Risk: Bristol Myers Squibb's two drugs, Eliquis and Opdivo, generated $24.4 billion in sales in 2022, accounting for about half of total revenue; however, both will lose market exclusivity in 2028, potentially leading to a significant sales decline and pressure on future growth.
- Pipeline Investment: The company has 50 compounds in development and aims to launch 10 new medicines by 2029, with Cobenfy already approved for schizophrenia; if it secures approval for Alzheimer's-related psychosis, it could greatly enhance commercial potential, but uncertainty remains as crucial phase 3 trial results are due later this year.
- Stable Dividend Yield: Bristol Myers Squibb offers a dividend yield of 4.6%, with payouts currently only 40% of projected 2026 earnings, meaning even if sales of Eliquis and Opdivo plummet, the company can still afford its dividends, providing investors with a solid margin of safety.
- Attractive Valuation: The stock trades at a low P/E ratio of 8.5, significantly below the industry average of 25, indicating the market's low growth expectations; however, if the company achieves moderate growth during the patent cliff, combined with a high dividend yield, investors could still see substantial returns.
See More
